Infant-type hemispheric glioma occurring at the cervicomedullary region in a 5-month-old infant: A case report with a special emphasis on molecular classification

Background High-grade gliomas in infancy are uncommon and have different clinical and molecular characteristics from those in adults. Recently, advances in molecular diagnostics have made progress in determining treatment strategies; however, the robust treatment has not yet been elucidated. We, herein, present a case of infantile glioma occurring at the cervicomedullary region. Case Description A 5-month-old infant developed left upper limb weakness and torticollis at 3 months of age. Magnetic resonance imaging revealed T2 hyperintensity from the medulla oblongata to the upper cervical cord. She underwent a biopsy for the lesion and pathological examination findings confirmed the presence of a high-grade astrocytoma with IDH wildtype-, H3K27M wildtype-, BRAF wildtype-, and ETV-NTRK3 fusion-positivity. Postoperatively, she underwent chemoradiotherapy, but she had marked tumor growth during the treatment. According to the new World Health Organization classification, the patient's tumor is an infantile "hemispheric" glioma. Conclusion The characteristics and prognosis of NTRK-fused glioma are not fully understood, it is noteworthy that these tumors commonly occur in the brainstem. Further studies are needed to determine the prognosis of each tumor type and its sensitivity to treatment. This information will help in the reclassification of the tumors and identification of the precise treatment of this rare type of tumor.

[1]  J. Hench,et al.  Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma , 2022, Pharmacology.

[2]  M. Massimino,et al.  Cervicomedullary Gliomas in Pediatric Age: A Systematic Review of the Literature and Tertiary Care Center Experience , 2022, Pediatric Neurosurgery.

[3]  C. Hastings,et al.  Oncogenic NTRK fusion in congenital spinal cord glioblastoma: sequencing directs treatment , 2021, The Lancet.

[4]  A. Drilon,et al.  Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors , 2021, Neuro-oncology.

[5]  K. Drummond,et al.  Pretreatment neutrophil-to-lymphocyte/monocyte-to-lymphocyte ratio as prognostic biomarkers in glioma patients , 2021, Journal of Neuroimmunology.

[6]  S. Baker,et al.  NTRK Fusions Can Co-Occur With H3K27M Mutations and May Define Druggable Subclones Within Diffuse Midline Gliomas. , 2021, Journal of neuropathology and experimental neurology.

[7]  Mariella G. Filbin,et al.  Molecular and clinicopathologic features of gliomas harboring NTRK fusions , 2020, Acta Neuropathologica Communications.

[8]  Amar Gajjar,et al.  The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma , 2014, Nature Genetics.

[9]  Douglas C. Miller,et al.  Induction chemotherapy and conformal radiation therapy for very young children with nonmetastatic medulloblastoma: Children's Oncology Group study P9934. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Busjahn,et al.  Genetic determination of chromosomal radiosensitivities in G0- and G2-phase human lymphocytes. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  J Nyman,et al.  Prognostic factors for acute and late skin reactions in radiotherapy patients. , 1996, International Journal of Radiation Oncology, Biology, Physics.

[12]  Report of Brain Tumor Registry of Japan (1984-2000). , 2009, Neurologia medico-chirurgica.